Viking Therapeutics (VKTX) has seen a dramatic decline in investor sentiment, plummeting from nearly $100 per share in early 2024 to just under $30 today. Initially viewed as a promising contender in the GLP-1 space, particularly with its VK2735 weight-loss drug candidate, the company now faces significant challenges from established competitors like Novo Nordisk and Eli Lilly, which have advanced their own treatments.
The shift in market perception stems from disappointing trial results and adverse side effects reported for VK2735, raising doubts about Viking’s ability to compete effectively. As its larger rivals continue to innovate with new therapies, Viking’s prospects appear increasingly uncertain. With approximately $603 million in cash but a burn rate of about $114 million per quarter, the company may soon need to raise additional funds, potentially leading to share dilution.
For market professionals, Viking Therapeutics serves as a cautionary tale in the biotech sector, highlighting the risks of investing in clinical-stage companies amid fierce competition and the necessity of robust trial data.
Source: fool.com